Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Free base in lipid
What ifWhat if a lipid vehicle carries sabcomeline as the free base?
Claim language“Crystalline sabcomeline pamoate”
A medium-chain triglyceride vehicle with a nonionic surfactant solubilizes the uncharged free base at a loading below its measured solubility. On aqueous dilution, the surfactant disperses the lipid as droplets that carry the dissolved compound.
1.1Ion exchange resin complex
What ifWhat if a sulfonated ion exchange resin binds protonated sabcomeline?
Claim language“sabcomeline pamoate”
Protonated sabcomeline displaces sodium ions from fixed sulfonate sites on cross-linked polymer beads. In aqueous media, dissolved cations compete for those sites and release sabcomeline into solution.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Blind samples for diffraction training
An analytical training lab prepares coded powder holders containing crystalline sabcomeline pamoate and other reference powders. Students collect X-ray powder diffraction patterns under the same measurement conditions for each holder and flag patterns with peaks at 17.8°, 19.0°, and 20.6° 2θ, each within ±0.2°. The instructor compares the reported matches with the sample key and uses the full reference patterns to review ambiguous results.
Component substitution
Xinafoate replaces the pamoate counterion
A salt screen pairs sabcomeline free base with 1-hydroxy-2-naphthoic acid to test xinafoate as the counterion. The screen combines the two components at a 1:1 molar ratio in warm ethanol, then cools the mixture and adds ethyl acetate to promote precipitation. Any recovered solid is filtered, dried, and analyzed by proton nuclear magnetic resonance for component ratio and by X-ray powder diffraction for its crystalline phase.
Parameter or scale variation
Reduced powder mass in diffraction wells
A flat-plate X-ray powder diffractometer uses a low-background silicon holder with a well 5 mm in diameter and 0.10 mm deep. About 2 mg of crystalline sabcomeline pamoate fills the well, and a straightedge levels the powder with the holder surface. With the incident beam footprint confined to the well, the instrument scans from 16.5° to 21.5° 2θ in 0.02° steps and records the three peak positions.
Seeded crystallization at three cooling rates
Three jacketed vessels receive 50 mL aliquots of the same saturated sabcomeline pamoate solution at a common starting temperature. Each vessel receives milled crystals of the target form at 0.5% by mass relative to dissolved salt after reaching the same low supersaturation. The vessels cool through a 15 °C interval at 0.1, 0.5, and 1.0 °C per minute, respectively, and hold at the final temperature for 60 minutes. Each batch is filtered and dried, then checked by X-ray powder diffraction for retention of the three characteristic peaks.
Combination with existing systems
Diffraction inside a humidity chamber
An X-ray powder diffractometer uses a sealed sample chamber with X-ray-transparent windows, a humidity probe, and separate dry and humidified gas inlets. A shallow bed of crystalline sabcomeline pamoate sits on the sample stage while the chamber holds 25 °C and steps from 20% to 50% to 80% relative humidity. At each humidity level, the instrument records a pattern after the probe reading stabilizes and tracks the position and intensity of the three characteristic peaks.
Automated or data-driven variant
Automated screening of paired diffraction scans
A motorized sample changer presents two independently packed holders from each sabcomeline pamoate lot to an X-ray powder diffractometer. Software subtracts a local baseline and fits a peak near each expected position at 17.8°, 19.0°, and 20.6° 2θ. It flags a match when both scans contain fitted peaks within ±0.2° of all three positions and each fitted peak height exceeds five times the local baseline noise. The software stores both traces and flags any disagreement for review.
Specific version of a part
Rotating capillary transmission scan
A thin-walled capillary holds crystalline sabcomeline pamoate and rotates during a copper Kα transmission scan to sample more crystallite orientations. The resulting pattern contains reflections at 17.8 ± 0.2°, 19.0 ± 0.2°, and 20.6 ± 0.2° 2θ.
Sealed powder diffraction holder
A thin polyimide film seals crystalline sabcomeline pamoate in a recessed reflection holder and limits moisture exchange during the scan. A copper Kα measurement records the three reflections at 17.8 ± 0.2°, 19.0 ± 0.2°, and 20.6 ± 0.2° 2θ above the film background.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1Crystalline sabcomeline pamoate exhibiting X-ray powder diffraction (XRPD) pattern 2θ peaks at 17.8±0.2, 19.0±0.2 and 20.6±0.2.
In some embodiments, Form C has X-ray powder diffraction peaks at approximately 17.5, 18.2, 19.0, 19.6, 20.1, and 22.6 °2θ using Cu Kα radiation.
A · US 2015/0299195 A1 · ¶ 366
In another alternative crystalline Hydrate 2 is characterized by x-ray powder diffraction peaks at 2Θ angles 9.0°, 10.4°, 14.9°, 15.5°, 17.8°, 18.4°, 18.7°, 20.7°, 21.2°, 21.9°, 22.7°, 24.6°, 25.9°, 26.3°, 27.4°, 28.0°, 29.5°, 31.0°, 31.7°, 32.6°, and 34.5°.
B · US 2023/0095799 A1 · ¶ 110
An empty cell means only that no passage was reproduced there.
Statements in these documents
Accordingly, new compounds and methods for modulating AKT genes and treating proliferation disorders, including cancer, are needed.
A · US 2015/0299195 A1 · ¶ 7
Identification of free base and salts of these compounds, and solid forms, such as amorphous forms, crystalline forms and mesomorphic forms, of the free base or salts of these compounds with optimal physical and chemical properties will advance the development of these compounds as pharmaceuticals.
A · US 2015/0299195 A1 · ¶ 7
There is a need for forms of this compound that are crystalline and otherwise have physical properties that are amenable effective delivery of this compound to the patient.
B · US 2023/0095799 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356829 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356829/, SHA-256 6b2b68a3874407e7cfa560eb97cd678b531722625fd1820301701a21e7b1f33e